The 9th Joint Conference of the University of Chicago and PUMCH Liver Surgery: Systematic Treatment and Surgical lmprovment of Hepatobiliary Pancreatic Diseases in the COVID Era

The University of Chicago Center in Beijing
20th floor, Culture Plaza
No. 59A Zhong Guan Cun Street
Haidian District Beijing 100872

We welcome you back to the annual conference sponsored jointly by the University of Chicago, PUMCH, and Journal Hepatobiliary Surgery and Nutrition (HBSN). This is the 9th conference and dates to the 1st year the University of Chicago Center in Beijing was established. The only interruption in the conference schedule was mandated by the COVID pandemic.

This year’s conference focused on the significant advances for the treatment of hepatobiliary pancreatic diseases that occurred despite the limitations brought on by COVID.

Science and Medicine makes progress even in the most extreme circumstances. We will highlight many of the systemic therapies that have occurred in the last several years that have made surgical treatment more successful and a look forward into the next series of advances that are on the cusp of clinical implementation.  We have gathered a very impressive list of internationally recognized experts in their fields to share the fruits of their clinical practice as well as insights into the future.  

J. Michael Millis, M.D.

• Professor of Surgery
• Faculty Director, University of Chicago
• Center in Beijing
• Vice Chair for Global Surgery
• Director, Hepatobiliary Surgery
• University of Chicago

Yilei Mao, M.D., Ph.D.

• Professor of Surgery
• Peking Union Medical College Hospital
• Vice Chair, Chinese Society for Liver Surgeons

More than 100 audience attended this conference.

AGENDA

Friday Sept. 8

13:00-13:05         Welcome and Introductions

Yilei Mao and J Michael Millis

13:05-13:15         Opening Address

Jiefu Huang, Beijing, China

Session I             HPB Surgery (Moderator - Yilei Mao)

13:15 - 13:45       Kiyoshi Hasegawa, Tokyo, Japan

Surgical Resection for Colorectal Liver Metastasis Combined with Pre- and/or Post- Operative Chemotherapy

13:45 - 14:00       Keynote Speech Discussion

14:00 - 14:30       Fabrizio Panaro, Montpellier, France

LVD (Liver Venous Deprivation) to Optimize the FRL (Future Remnant Liver)

14:30 - 15:00       Guido Torzilli, Rozzano, Italy

Scaffold Sparing Surgery for Expanding Surgical Solutions for Treating Liver Tumors

15:00 - 15:30       Sarah Hays, Chicago, USA

Advances in Minimally Invasive Pancreatic Surgery

15:30 - 16:00       Shunda Du, Beijing, China

Application of Urinary Proteomics in Hepatocellular Carcinoma Diagnosis

16:00-16:15         Break

Session II          Non Surgical HPB I (Moderator - Fabrizio Panaro)

16:15 - 16:45       Tan To Cheung, Hong Kong, China

Update of Surgical Management of HCC in the Era of Immunotherapy

16:45 - 17:15       Mark A. Taylor, Belfast, UK

Impact of the Covid-19 Pandemic on HPB Surgery in the UK and Lessons Learnt

17:15 - 17:45       J Michael Millis, Chicago, USA

Cellular Therapy for HPB Malignancies - What Does the Future Hold and How Do We Get There

Saturday Sept. 9

Session III         OLT (Moderator – J Michael Millis)

08:30 - 09:00       Chao-Long Chen, Taiwan, China

Evolving Strategies in Living Donor Liver Transplantation for Hepatocellular Carcinoma

09:00-09:15         Keynote Speech Discussion

09:15 - 09:45       Simon C. Robson, Boston, USA (Online Speech)

Translational Advances in Purinergic Signaling: Harnessing the Power of ATP to Control Inflammation and Modulate Angiogenesis

09:45 - 10:15       Jiayin Yang, Chengdu, China

Precision Surgery in Liver Transplantation

10:15 - 10:45       Seoung Hoon Kim, Seoul, South Korea

Living Donor Surgery: Extending Indication and Improving Outcomes

10:45 - 11:15       Wen Yuan Chung, Leicester, UK

Research Applications of Ex Vivo liver Perfusion Models

11:15-11:30         Break

Session IV          COVID (Moderator-Huabiao Chen, Ningbo, China)

11:30- 12:00        Andy Liao, Chicago, USA (Online Speech)

Emerging Systemic Therapies for Biliary Tract Cancers

12:00-12:30         Silvia Sookoian, Buenos Aires, Argentina

COVID-19 and NASH Cirrhosis: Disease Mechanisms, and the Cross-talk with Immune Response

12:30-13:00         Carlos J Pirola, Buenos Aires, Argentina

Novel Insights from Multi-omics Data on SARS-CoV2 Infection and Non-alcoholic Fatty Liver Disease

13:00-14:00         Lunch (All participants) Zhengda Tianqing Special Session

Session V           Non Surgical Treatment (Moderator - Dandan Hu, Guangzhou, China)

14:00-14:30         Mohammed Eslam, Sydney, Australia

MAFLD: What Does the Evidence Say?

14:30- 15:00        Wenhui Lou, Shanghai, China

Current Diagnosis and Treatment of Pancreatic Cancer in China

15:00-15:30         Jinhong Chen, Shanghai, China

Precision Exploration of Systemic Therapy for Hepatocellular Carcinoma

15:30-15:45        Break

Session VI         Non Surgical HPB Malignancy (Moderator - Haitao Zhao, Beijing, China)

15:45 -16:15        Björn Nashan, Hamburg, Germany (currently working in Hefei, China)

Quality Assessment and Management in Liver Transplantation

16:15-16:45         Ming-Hua Zheng, Wenzhou, China

Clinical FLD Cohort Development and Achievement Transformation: Wenzhou's Practice

16:45-17:15         Xiang-Dong Wang, Boston, USA

Nutritional Intervention on Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma

17:15-17:30         Closing Remarks

Yilei Mao and J Michael Millis